These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1486772)

  • 21. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women.
    Straznicky NE; Barrington VE; Branley P; Louis WJ
    J Hypertens; 1998 Mar; 16(3):357-68. PubMed ID: 9557929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function.
    Prasad RN; Koh S; Ratnam SS
    Contraception; 1989 Apr; 39(4):369-83. PubMed ID: 2524360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
    Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
    Renier M; Buytaert P
    Contraception; 1991 May; 43(5):413-21. PubMed ID: 1914456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women.
    Sirtori CR; Calabresi L; Franceschini G; Gianfranceschi G; Zoppi F; Winkler S; Bilotta P; Zampetti A
    Atherosclerosis; 1990 Oct; 84(2-3):203-11. PubMed ID: 2149269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
    Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
    Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose and lipid metabolism with triphasic oral contraceptives in women with history of gestational diabetes.
    Kung AW; Ma JT; Wong VC; Li DF; Ng MM; Wang CC; Lam KS; Young RT; Ma HK
    Contraception; 1987 Mar; 35(3):257-69. PubMed ID: 3111786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism.
    Coata G; Ventura F; Lombardini R; Ciuffetti G; Cosmi EV; Di Renzo GC
    Contraception; 1995 Sep; 52(3):151-7. PubMed ID: 7587186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.